ATE234095T1 - Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington. - Google Patents

Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington.

Info

Publication number: ATE234095T1
Authority: AT; Austria
Prior art keywords: huntington; epilepsy; treatment; disease; rapamycin
Prior art date: 1995-12-07

Application number

AT96308786T

Other languages

English (en)

Inventor

Stephen Shi-Hsun Lin

Katherine Lu Molnar-Kimber

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-07

Filing date

1996-12-04

Publication date

2003-03-15

1996-12-04 Application filed by Wyeth Corp filed Critical Wyeth Corp

2003-03-15 Application granted granted Critical

2003-03-15 Publication of ATE234095T1 publication Critical patent/ATE234095T1/de

Links

208000023105 Huntington disease Diseases 0.000 title 2
206010015037 epilepsy Diseases 0.000 title 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 2
229960002930 sirolimus Drugs 0.000 title 2
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 title 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Physiology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT96308786T 1995-12-07 1996-12-04 Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington. ATE234095T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US833795P	1995-12-07	1995-12-07

Publications (1)

Publication Number	Publication Date
ATE234095T1 true ATE234095T1 (de)	2003-03-15

Family

ID=21731060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96308786T ATE234095T1 (de)	1995-12-07	1996-12-04	Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington.

Country Status (23)

Country	Link
EP (1)	EP0778023B1 (de)
JP (1)	JPH09183727A (de)
KR (1)	KR970032856A (de)
CN (1)	CN1112925C (de)
AR (1)	AR008747A1 (de)
AT (1)	ATE234095T1 (de)
AU (1)	AU700653B2 (de)
BR (1)	BR9605895A (de)
CA (1)	CA2192298A1 (de)
CZ (2)	CZ354496A3 (de)
DE (1)	DE69626610T2 (de)
DK (1)	DK0778023T3 (de)
ES (1)	ES2188730T3 (de)
HU (1)	HUP9603370A3 (de)
IL (1)	IL119778A (de)
MX (1)	MX9606131A (de)
NO (1)	NO309966B1 (de)
NZ (1)	NZ299888A (de)
PT (1)	PT778023E (de)
SI (1)	SI0778023T1 (de)
SK (1)	SK154796A3 (de)
TW (1)	TW427904B (de)
ZA (1)	ZA9610245B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1002535A1 (de) *	1998-10-28	2000-05-24	Hrissanthi Ikonomidou	Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs
US6417189B1 (en) *	1999-11-12	2002-07-09	Gpi Nil Holdings, Inc.	AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en)	1999-11-12	2007-08-07	Gliamed, Inc.	Aza compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) *	2000-03-22	2003-11-28	Centre Nat Rech Scient	Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (en) *	2000-04-17	2001-10-25	Gpi Nil Holdings, Inc.	Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) *	2001-07-19	2001-09-12	Isis Innovation	Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en)	2001-10-10	2007-04-10	Wyeth Corp	Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) *	2002-03-13	2003-09-18	Wyeth	Method of inhibiting cell death
CA2521313A1 (en)	2003-04-09	2004-10-28	Wyeth	Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
EP1622625A1 (de) *	2003-04-09	2006-02-08	Wyeth	Pharmazeutische zusammensetzungen für die intranasale verabreichung von [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0] non-1 (7)-en-2-yl)alkyl] phosphonsäure und derivaten und anwendungsverfahren dafür
US20070155771A1 (en) *	2003-04-11	2007-07-05	David Rubinsztein	Methods and means for treating protein conformational disorders
US7485706B2 (en) *	2003-07-30	2009-02-03	The Board Of Trustees Of The Leland Stanford Junior University	Neurodegenerative protein aggregation inhibition methods and compounds
GT200400213A (es)	2003-10-22	2007-09-05		Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
CA2590254A1 (en)	2004-12-20	2006-06-29	Wyeth	Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
AU2005319454B2 (en)	2004-12-20	2012-08-09	Wyeth	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
JP4857071B2 (ja) *	2006-10-12	2012-01-18	潤平笹部	筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (de)	2007-11-30	2009-06-03	Pharnext	Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
EP2135607A1 (de)	2008-06-18	2009-12-23	Pharnext	Kombination aus Pilocarpin und Methimazol zur Behandlung der Charcot-Marie-Tooth Krankheit und verwandten Erkrankungen
AU2010233073B2 (en) *	2009-04-10	2014-07-31	Haiyan Qi	Novel anti-aging agents and methods to identify them
EP2263665A1 (de)	2009-06-02	2010-12-22	Pharnext	Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US9393241B2 (en)	2009-06-02	2016-07-19	Pharnext	Compositions for treating CMT and related disorders
WO2011009193A1 (en) *	2009-07-24	2011-01-27	Institut National De La Recherche Scientifique	Combinations of curcummoids and mtor inhibitors for the treatment of tauopathies
US9121859B2 (en)	2012-12-04	2015-09-01	Siemens Healthcare Diagnostics Inc.	Compounds and methods for determination of FKBP-binding immunosuppressant drugs
AU2014276856B2 (en)	2013-06-05	2018-11-15	Pharnext	Stable oral solutions for combined API
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
US10383870B2 (en)	2016-06-10	2019-08-20	Pharnext	Early treatment of CMT disease
GB2583239A (en) *	2017-11-15	2020-10-21	Univ Vanderbilt	Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
CN114366738A (zh) *	2021-12-20	2022-04-19	中国人民解放军军事科学院军事医学研究院	雷帕霉素在促进神经干细胞扩增中的用途
CN119639757B (zh) *	2024-12-11	2025-07-22	庐山市绿游生态农业开发有限公司	一种红藻氨酸受体及其抑制剂在防治橘小实蝇中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
JPH04230389A (ja) *	1990-07-16	1992-08-19	American Home Prod Corp	ラパマイシン誘導体
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
IL101353A0 (en) *	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) *	1991-06-05	1992-12-10	Schering Ag	Neue kombinationspraeparate zur behandlung des morbus parkinson
ZA924953B (en) *	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5260299A (en) *	1992-03-05	1993-11-09	American Home Products Corporation	Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) *	1993-09-30	1994-11-28	American Home Prod	Multi-component oral rapamycin formulation

1996
- 1996-11-28 TW TW085114700A patent/TW427904B/zh not_active IP Right Cessation
- 1996-12-04 DK DK96308786T patent/DK0778023T3/da active
- 1996-12-04 ES ES96308786T patent/ES2188730T3/es not_active Expired - Lifetime
- 1996-12-04 SI SI9630586T patent/SI0778023T1/xx unknown
- 1996-12-04 CZ CZ963544A patent/CZ354496A3/cs unknown
- 1996-12-04 CZ CZ9864A patent/CZ6498A3/cs unknown
- 1996-12-04 EP EP96308786A patent/EP0778023B1/de not_active Expired - Lifetime
- 1996-12-04 AT AT96308786T patent/ATE234095T1/de not_active IP Right Cessation
- 1996-12-04 SK SK1547-96A patent/SK154796A3/sk unknown
- 1996-12-04 DE DE69626610T patent/DE69626610T2/de not_active Expired - Fee Related
- 1996-12-04 PT PT96308786T patent/PT778023E/pt unknown
- 1996-12-05 MX MX9606131A patent/MX9606131A/es unknown
- 1996-12-05 NZ NZ299888A patent/NZ299888A/en unknown
- 1996-12-05 AU AU74178/96A patent/AU700653B2/en not_active Ceased
- 1996-12-05 KR KR1019960062011A patent/KR970032856A/ko not_active Ceased
- 1996-12-05 ZA ZA9610245A patent/ZA9610245B/xx unknown
- 1996-12-06 CN CN96123098A patent/CN1112925C/zh not_active Expired - Fee Related
- 1996-12-06 BR BR9605895A patent/BR9605895A/pt not_active Application Discontinuation
- 1996-12-06 NO NO965238A patent/NO309966B1/no not_active IP Right Cessation
- 1996-12-06 IL IL11977896A patent/IL119778A/xx not_active IP Right Cessation
- 1996-12-06 JP JP8326582A patent/JPH09183727A/ja active Pending
- 1996-12-06 HU HU9603370A patent/HUP9603370A3/hu unknown
- 1996-12-06 AR ARP960105543A patent/AR008747A1/es not_active Application Discontinuation
- 1996-12-06 CA CA002192298A patent/CA2192298A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ299888A (en)	2001-02-23
BR9605895A (pt)	1998-08-18
NO965238L (no)	1997-06-09
IL119778A0 (en)	1997-03-18
CZ6498A3 (cs)	1998-06-17
CN1112925C (zh)	2003-07-02
SK154796A3 (en)	1997-09-10
SI0778023T1 (en)	2003-08-31
MX9606131A (es)	1997-08-30
IL119778A (en)	1999-07-14
HUP9603370A2 (en)	1997-05-28
AU700653B2 (en)	1999-01-14
NO965238D0 (no)	1996-12-06
DK0778023T3 (da)	2003-06-30
DE69626610D1 (de)	2003-04-17
CZ354496A3 (cs)	1998-03-18
CN1159915A (zh)	1997-09-24
JPH09183727A (ja)	1997-07-15
DE69626610T2 (de)	2003-10-02
EP0778023A1 (de)	1997-06-11
TW427904B (en)	2001-04-01
HUP9603370A3 (en)	1998-12-28
CA2192298A1 (en)	1997-06-08
NO309966B1 (no)	2001-04-30
EP0778023B1 (de)	2003-03-12
HU9603370D0 (en)	1997-01-28
PT778023E (pt)	2003-06-30
AR008747A1 (es)	2000-02-23
KR970032856A (ko)	1997-07-22
AU7417896A (en)	1997-06-12
ES2188730T3 (es)	2003-07-01
ZA9610245B (en)	1998-06-05

Legal Events

Date

Code

Title

Description

2003-07-15

UEP

Publication of translation of european patent specification

Ref document number: 0778023

Country of ref document: EP

2008-09-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE234095T1 (de)	2003-03-15	Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington.
DE3870376D1 (de)	1992-05-27	Blattfoermiges material zur haut- oder haarbehandlung, verfahren zu dessen herstellung und aus diesem material hergestellte gegenstaende.
DE69626961D1 (de)	2003-04-30	Wegwerfkleidungsstück, verfahren und vorrichtung zu dessen herstellung
DE69532990D1 (de)	2004-06-09	Ein zusammengesetzter gegenstand für die behandlung von dermatologischen narben, ein verfahren zur herstellung des gegenstandes und dessen verwendung
ATE252901T1 (de)	2003-11-15	Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE69107370D1 (de)	1995-03-23	Dekorativer, verschleissfester Mehrschichtstoff und Verfahren zu seiner Herstellung.
ATE280580T1 (de)	2004-11-15	Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen
HUP9800467A3 (en)	1999-01-28	Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
DE69426320D1 (de)	2000-12-28	Verwendung von silikon/fluorsilikon kopolymeröl zur herstellung eines arzneimittels zur behandlung von augenerkrankungen
DE69429806D1 (de)	2002-03-21	Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung
DE69925488D1 (de)	2005-06-30	Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
NO975662D0 (no)	1997-12-05	Anvendelse av 1,2,4-triazolderivater for fremstilling av et medikament for behandling av cancer
CA2181090A1 (en)	1997-01-15	Apparatus for dividing into separate parts an assembly comprising heart and lungs
ATE212034T1 (de)	2002-02-15	Derivate von 5-0-desosaminyl-6-0-methyl erythronolid a, ihre verfahren zur herstellung und verwendung zur herstellung von arzneimitteln
DE69509430D1 (de)	1999-06-10	Kosmetische Zusammensetzung für Masken zur Reinigung der Haut, die sphäroidale Polyamid-Partikel vorgegebener Grösse enthält
DE69637449D1 (de)	2008-04-10	Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
DE602004016491D1 (de)	2008-10-23	Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
DE69512977D1 (de)	1999-12-02	Material für die Behandlung von Tierexkrementen und Verfahren zu dessen Herstellung
ATE211911T1 (de)	2002-02-15	Tiagabinhydrochlorid enthaltendes arzneimittel und verfahren zu dessen herstellung
DE3768150D1 (de)	1991-04-04	Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
ATE216235T1 (de)	2002-05-15	Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
ATE263565T1 (de)	2004-04-15	Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
FR2737664B1 (fr)	1998-12-24	Procede pour la production d'un dispositif implantable hemocompatible, et dispositif implantable ainsi produit
DE69915848D1 (de)	2004-04-29	Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE69424415D1 (de)	2000-06-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit